Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease
Completed · Phase 3
Conditions studied: Alzheimer Disease
In brief
This study will evaluate whether visual interpretation of flortaucipir-PET (positron emission tomography) scans, examining patterns of tracer uptake at baseline, can predict the rate of clinically-meaningful cognitive decline due to AD after 18 months. All scans are acquired from cohorts of a previously completed study, I8D-MC-AZES (NCT02245737, lanabecestat, Eli Lilly and Company sponsor).
Key facts
- Study ID
- NCT03901105
- Run by
- Avid Radiopharmaceuticals
- People needed
- 205
- Starts
- 2019-03-28
- Expected to finish
- 2019-04-28
- Last updated by the study team
- 2020-08-28
Who can join
Age: 55 and older, up to 85. Sex: any. Healthy volunteers: not accepted.
Where it is running
- American College of Radiology — Philadelphia, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.